论文部分内容阅读
目的观察环氧合酶(COX)-2在肝癌细胞系(HepG2、HLE、HG116、SMMC7402)中蛋白、mRNA水平的表达,探讨COX-2的选择性抑制剂美洛昔康对肝癌细胞系HepG2的生长抑制作用。方法用逆转录聚合酶链反应(RTPCR)和细胞免疫化学方法研究COX-2在人肝癌细胞系中的表达,并用噻唑蓝(MTT)法和流式细胞仪检测COX2的抑制剂美洛昔康对人肝癌细胞系HepG2的生长抑制作用。结果应用免疫组织化学和RTPCR在4种肝癌细胞系中检测COX-2蛋白及其mRNA均有阳性表达。美洛昔康对肝癌细胞系HepG2有较明显的生长抑制作用(P<0.01),并呈时间、剂量依赖性。时间相同时,50μmol/L浓度组抑制率最高,在1、3、5d的抑制率分别为12.5%、39.1%、56.1%,与5、20μmol/L组比较差异有统计学意义(P<0.05);5μmol/L组与20μmol/L组之间差异无统计学意义(P>0.05)。浓度相同时,第5天抑制率最高,5、20、50μmol/L组抑制率分别可达15.6%、28.1%、56.1%,第5天与第1天差异有统计学意义(P<0.01),结论美洛昔康作为COX-2选择性抑制剂对肝癌细胞有明显的生长抑制作用,为肝癌的防治提供了一个新的实验依据。
Objective To observe the expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma cell lines (HepG2, HLE, HG116 and SMMC7402), and to investigate the effect of meloxicam, a selective inhibitor of COX-2, on hepatocellular carcinoma cell line HepG2 Growth inhibitory effect. Methods The expression of COX-2 in human hepatocellular carcinoma cell line was detected by reverse transcriptase-polymerase chain reaction (RTPCR) and immunocytochemistry. The expression of COX2 inhibitor meloxicam was detected by MTT assay and flow cytometry Inhibitory effect on human hepatoma cell line HepG2. Results Immunohistochemistry and RTPCR were used to detect the expression of COX-2 protein and its mRNA in all four hepatoma cell lines. Meloxicam had a more obvious growth inhibitory effect on HepG2 cell line (P <0.01) in a time-and dose-dependent manner. At the same time, the inhibition rate was highest at 50μmol / L and 12.5%, 39.1% and 56.1% respectively at 1, 3 and 5 days, with statistical significance (P <0.05) ). There was no significant difference between 5μmol / L group and 20μmol / L group (P> 0.05). At the same concentration, the inhibition rate was the highest on the fifth day, and the inhibitory rates were 15.6%, 28.1% and 56.1% at 5, 20 and 50μmol / L groups, respectively. There was a significant difference between the 5th and the 1st day (P <0.01) .Conclusion Meloxicam as a selective inhibitor of COX-2 has a significant inhibitory effect on hepatocarcinoma cells and provides a new experimental basis for the prevention and treatment of hepatocellular carcinoma.